Latest Dimebolin Stories
SAN FRANCISCO, Feb. 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will be a featured speaker on a panel entitled, "Alzheimer's Disease: A Panel To Remember," at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, at 9:00 a.m. Eastern Time at the Waldorf=Astoria in New York. Dr. Hung will also provide a corporate update later in the day on Tuesday, February 9, at 11:30 a.m....
WALTHAM, Mass., Jan. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Pfizer/Medivation's Dimebon shows efficacy in two ongoing clinical trials in moderate to severe Alzheimer's disease that is equivalent to the impressive clinical trial data it has already shown to date in mild to moderate patients, these positive data would promote the use of Dimebon throughout the course of the disease....
SAN FRANCISCO, Dec. 17 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced changes to its organizational structure to support anticipated growth as the company prepares to transition from a development stage company to a commercial organization. As part of this transition, chief financial officer (CFO) Patrick Machado will transition to a new role, chief business officer (CBO), in which he will oversee strategic planning, business development, alliance management and intellectual...
SAN FRANCISCO, Nov. 11 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at Lazard Capital Markets Sixth Annual Healthcare conference on Wednesday, November 18, at 8:30 a.m. Eastern Time at the St. Regis Hotel in New York. Dr. Hung will provide an overview of Medivation and its clinical development programs for dimebon (latrepirdine) for Alzheimer's and Huntington diseases and MDV3100 for...
SAN FRANCISCO, Nov. 4 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the third quarter ended September 30, 2009. "With the signing of our agreement for MDV3100 with Astellas last week, we now have a first-class partner with a global reach, leading commercial presence in the urology space, and strategic focus on oncology. This achievement marks our second major collaboration in just over a year's time, bringing...
SAN FRANCISCO, Oct. 28 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss third quarter 2009 financial results and provide a general business update on Wednesday, November 4, 2009, at 4:30 p.m. Eastern Time. A press release for the third quarter ended September 30, 2009 will be released after markets close on November 4, 2009. Interested parties may call 877-874-1563 from the U.S. or...
SAN FRANCISCO, Oct. 26 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference at 8:30 a.m. Eastern Time tomorrow, Tuesday, October 27, to discuss partnering plans for MDV3100, Medivation's investigational drug which is currently in Phase 3 testing for the treatment of prostate cancer. Teleconference/Webcast Details To participate in the live call on Tuesday, October 27, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), please dial...
SAN FRANCISCO, Oct. 23 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the appointment of Hank Mansbach, M.D., as vice president of medical affairs. Dr. Mansbach will lead Medivation's medical affairs activities for dimebon (latrepirdine*), the company's Phase 3 candidate for the treatment of Alzheimer's and Huntington diseases, and MDV3100, which is in Phase 3 clinical development for the treatment of advanced prostate cancer. "Hank brings a vast array of...
SAN FRANCISCO, Aug. 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the second quarter ended June 30, 2009. "In the past several months, we completed enrollment in our confirmatory, pivotal Phase 3 CONNECTION trial of dimebon (latrepirdine*) in Alzheimer's disease; initiated the pivotal Phase 3 HORIZON trial of dimebon in Huntington disease; reported important clinical data from both our dimebon and MDV3100...
SAN FRANCISCO, July 29 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss second quarter 2009 financial results and provide a general business update on Wednesday, August 5, 2009, at 4:30 p.m. Eastern Time. A press release for the second quarter ended June 30, 2009 will be released after markets close on August 5, 2009. Interested parties may call 888-287-5532 from the U.S. or +1-719-325-2124...
